Home > Maligne hematologie > Myeloïde ziekten > Acute myeloïde leukemie > AML (incl. APL) > Hovon 156

Hovon 156

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 21-7-2024, 19:50